- Home
- WEX vs AXSM Comparison
WEX vs AXSM Comparison
Compare WEX & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEX
- AXSM
- Stock Information
- Founded
- WEX 1983
- AXSM 2012
- Country
- WEX United States
- AXSM United States
- Employees
- WEX N/A
- AXSM N/A
- Industry
- WEX Business Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- WEX Consumer Discretionary
- AXSM Health Care
- Exchange
- WEX Nasdaq
- AXSM Nasdaq
- Market Cap
- WEX 5.8B
- AXSM 5.1B
- IPO Year
- WEX 2005
- AXSM 2015
- Fundamental
- Price
- WEX $167.27
- AXSM $122.00
- Analyst Decision
- WEX Hold
- AXSM Strong Buy
- Analyst Count
- WEX 13
- AXSM 17
- Target Price
- WEX $179.82
- AXSM $175.76
- AVG Volume (30 Days)
- WEX 337.6K
- AXSM 518.7K
- Earning Date
- WEX 10-23-2025
- AXSM 08-04-2025
- Dividend Yield
- WEX N/A
- AXSM N/A
- EPS Growth
- WEX 37.64
- AXSM N/A
- EPS
- WEX 7.93
- AXSM N/A
- Revenue
- WEX $2,598,200,000.00
- AXSM $495,033,000.00
- Revenue This Year
- WEX $1.02
- AXSM $64.05
- Revenue Next Year
- WEX $5.27
- AXSM $56.46
- P/E Ratio
- WEX $21.10
- AXSM N/A
- Revenue Growth
- WEX N/A
- AXSM 69.83
- 52 Week Low
- WEX $110.45
- AXSM $75.56
- 52 Week High
- WEX $217.47
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- WEX 47.65
- AXSM 68.86
- Support Level
- WEX $166.93
- AXSM $119.93
- Resistance Level
- WEX $173.61
- AXSM $124.61
- Average True Range (ATR)
- WEX 3.05
- AXSM 3.20
- MACD
- WEX -1.14
- AXSM 0.94
- Stochastic Oscillator
- WEX 9.99
- AXSM 84.49
About WEX WEX Inc. common stock
WEX Inc is a provider of corporate payment solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. The company's prime end market is the United States of America.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.